Logo do repositório
 
Publicação

Case report: Primary CDK4/6 inhibitor and endocrine therapy in locally advanced breast cancer and its effect on gut and intratumoral microbiota

2024Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorVilhais, Guilherme
dc.contributor.authorAlpuim Costa, Diogo
dc.contributor.authorFontes-Sousa, Mário
dc.contributor.authorRibeiro, Pedro Casal
dc.contributor.authorMartinho, Filipa
dc.contributor.authorBotelho de Sousa, Carolina
dc.contributor.authorSantos, Catarina Rodrigues
dc.contributor.authorNegreiros, Ida
dc.contributor.authorCanastra, Ana
dc.contributor.authorBorralho, Paula
dc.contributor.authorGuia Pereira, Ana
dc.contributor.authorMarçal, Cristina
dc.contributor.authorGermano Sousa, José
dc.contributor.authorChaleira, Renata
dc.contributor.authorRocha, Júlio César
dc.contributor.authorCalhau, Conceição
dc.contributor.authorFaria, Ana
dc.date.accessioned2024-06-07T14:47:55Z
dc.date.available2024-06-07T14:47:55Z
dc.date.issued2024
dc.descriptionCopyright © 2024 Vilhais, Alpuim Costa, Fontes-Sousa, Ribeiro, Martinho, Botelho de Sousa, Santos, Negreiros, Canastra, Borralho, Guia Pereira, Marçal, Germano Sousa, Chaleira, Rocha, Calhau and Faria. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.pt_PT
dc.description.abstractLocally advanced breast cancer poses significant challenges to the multidisciplinary team, in particular with hormone receptor (HR) positive, HER2-negative tumors that classically yield lower pathological complete responses with chemotherapy. The increasingly significant use of CDK 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) in different breast cancer settings has led to clinical trials focusing on this strategy as a primary treatment, with promising results. The impact of the microbiota on cancer, and vice-versa, is an emerging topic in oncology. The authors report a clinical case of a postmenopausal female patient with an invasive breast carcinoma of the right breast, Luminal B-like, staged as cT4cN3M0 (IIIB). Since the lesion was considered primarily inoperable, the patient started letrozole and ribociclib. Following 6 months of systemic therapy, the clinical response was significant, and surgery with curative intent was performed. The final staging was ypT3ypN2aM0, R1, and the patient started adjuvant letrozole and radiotherapy. This case provides important insights on primary CDK4/6i plus ET in locally advanced unresectable HR+/HER2- breast cancer and its potential implications in disease management further ahead. The patient's gut microbiota was analyzed throughout the disease course and therapeutic approach, evidencing a shift in gut microbial dominance from Firmicutes to Bacteroidetes and a loss of microbial diversity following 6 months of systemic therapy. The analysis of the intratumoral microbiota from the surgical specimen revealed high microbial dissimilarity between the residual tumor and respective margins.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFront Oncol. 2024 Mar 27:14:1360737pt_PT
dc.identifier.doi10.3389/fonc.2024.1360737pt_PT
dc.identifier.eissn2234-943X
dc.identifier.urihttp://hdl.handle.net/10451/65009
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontierspt_PT
dc.relation.publisherversionhttps://www.frontiersin.org/journals/oncologypt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCDK 4/6 inhibitorspt_PT
dc.subjectBreast cancerpt_PT
dc.subjectGut microbiomept_PT
dc.subjectGut microbiotapt_PT
dc.subjectIntratumoral microbiotapt_PT
dc.subjectMicrobiomept_PT
dc.subjectMicrobiotapt_PT
dc.titleCase report: Primary CDK4/6 inhibitor and endocrine therapy in locally advanced breast cancer and its effect on gut and intratumoral microbiotapt_PT
dc.title.alternativePrimary CDK4/6 inhibitor and endocrine therapy in locally advanced breast cancer and its effect on gut and intratumoral microbiota : case reportpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleFrontiers in Oncologypt_PT
oaire.citation.volume14pt_PT
person.familyNameBorralho Nunes
person.givenNamePaula
person.identifier.ciencia-idE91A-B8A4-D3B9
person.identifier.orcid0000-0002-8556-2090
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication7b69ff94-b9aa-40a2-9b1e-142008fbbece
relation.isAuthorOfPublication.latestForDiscovery7b69ff94-b9aa-40a2-9b1e-142008fbbece

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Primary_CDK46.pdf
Tamanho:
2.72 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FM - Artigos em Revistas Internacionais